A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
Sosei Group said on July 20 that it will be acquiring all shares of the Japanese and South Korean arms of Switzerland-based Idorsia Pharmaceuticals for roughly 65 billion yen, making them wholly owned subsidiaries. Under this deal, Sosei will obtain…
To read the full story
Related Article
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- Shionogi Sole Distributor of Nxera’s Insomnia Med in Japan
October 2, 2024
- Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
September 8, 2023
BUSINESS
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
- Astellas to Offload Seroquel, “G1” LLP, to LTL Pharma
January 17, 2025
- J-TEC, Kobe Cell Therapy Player Form Capital Alliance
January 16, 2025
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- AnGes Partners with Stanford on Cancer Therapy Research
January 16, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…